Moderna Inc.'s Phase III development plan for its COVID-19 vaccine mRNA-1273 calls for enrolling roughly 30,000 patients in the US who will be treated with the 100 µg dose – the midrange dose studied in the Phase I trial. The biotech announced on 11 June that it finalized the Phase III study protocol based on feedback from the US Food and Drug Administration.
The company said it is advancing the 100µg dose because it is the optimal dose level to maximize the immune...







